Pharmacological Treatment of Bipolar Disorder

2002 ◽  
pp. 191-279 ◽  
Author(s):  
Charles L. Bowden
Keyword(s):  
Bipolar Disorder ◽  
Pharmacological Treatment

scholarly journals The incidence, psychiatric co-morbidity and pharmacological treatment of severe mental disorders in children and adolescents

2018 ◽  
Vol 49 ◽  
pp. 16-22 ◽  
Author(s):  
Ragnar Nesvåg ◽  
Jørgen G. Bramness ◽  
Marte Handal ◽  
Ingeborg Hartz ◽  
Vidar Hjellvik ◽  
...  
Keyword(s):  
Bipolar Disorder ◽  
Mental Disorders ◽  
Mental Disorder ◽  
Children And Adolescents ◽  
Pharmacological Treatment ◽  
Depressive Episode ◽  
Psychotic Symptoms ◽  
Severe Mental Disorder ◽  
Co Morbidity ◽  
First Time

AbstractBackgroundAntipsychotic drug use among children and adolescents is increasing, and there is growing concern about off-label use and adverse effects. The present study aims to investigate the incidence, psychiatric co-morbidity and pharmacological treatment of severe mental disorder in Norwegian children and adolescents.MethodsWe obtained data on mental disorders from the Norwegian Patient Registry on 0–18 year olds who during 2009–2011 were diagnosed for the first time with schizophrenia-like disorder (International Classification of Diseases, 10th revision codes F20-F29), bipolar disorder (F30-F31), or severe depressive episode with psychotic symptoms (F32.3 or F33.3). Data on filled prescriptions for psychotropic drugs were obtained from the Norwegian Prescription Database.ResultsA total of 884 children and adolescents (25.1 per 100 000 person years) were first time diagnosed with schizophrenia-like disorder (12.6 per 100 000 person years), bipolar disorder (9.2 per 100 000 person years), or severe depressive episode with psychotic symptoms (3.3 per 100 000 person years) during 2009–2011. The most common co-morbid mental disorders were depressive (38.1%) and anxiety disorders (31.2%). Antipsychotic drugs were prescribed to 62.4% of the patients, 72.0% of the schizophrenia-like disorder patients, 51.7% of the bipolar disorder patients, and 55.4% of the patients with psychotic depression. The most commonly prescribed drugs were quetiapine (29.5%), aripiprazole (19.6%), olanzapine (17.3%), and risperidone (16.6%).ConclusionsWhen a severe mental disorder was diagnosed in children and adolescents, the patient was usually also prescribed antipsychotic medication. Clinicians must be aware of the high prevalence of depressive and anxiety disorders among early psychosis patients.

Psychosocial Treatments for Bipolar Disorder

2007 ◽  
pp. 309-322 ◽  
Author(s):  
David J. Miklowitz ◽  
W. Edward Craighead
Keyword(s):  
Bipolar Disorder ◽  
Medication Adherence ◽  
Treatment Period ◽  
Pharmacological Treatment ◽  
Psychosocial Interventions ◽  
Improve Medication Adherence ◽  
Coping With Stress ◽  
Adherence To Medication ◽  
Bipolar Patients

Whereas pharmacological interventions remain the primary treatment for bipolar disorder, adjunctive psychosocial interventions have the potential to increase adherence to medication regimens, decrease hospitalizations and relapses, improve quality of life, and enhance mechanisms for coping with stress. Controlled studies have established that individual, family, and group psychoeducation, designed to provide information to bipolar patients and their families about the disorder, its pharmacological treatment, and the treatments’ side effects, leads to lower rates of recurrence and greater adherence to pharmacological treatment among bipolar patients. Type 1 and 2 studies have evaluated cognitive behavioral therapy (CBT) as an ancillary treatment. These studies indicate that CBT is associated with better medication adherence and significantly fewer recurrences and/or rehospitalizations. One Type 1 study has evaluated the effectiveness of IPSRT (interpersonal and social rhythm therapy) for bipolar disorder. IPSRT demonstrated its greatest symptomatic effects during a maintenance treatment period, especially if bipolar patients had been successful in stabilizing their daily and nightly routines during an acute treatment period. Finally, four Type 1 studies in adult and pediatric patients have shown that marital/ family therapy may be effectively combined with pharmacotherapy to reduce recurrences and improve medication adherence and family functioning.

Methodological differences between pharmacological treatment guidelines for bipolar disorder: what to do for the clinicians?

2013 ◽  
Vol 54 (4) ◽  
pp. 309-320 ◽  
Author(s):  
Ludovic Samalin ◽  
Sebastien Guillaume ◽  
Philippe Courtet ◽  
Mocrane Abbar ◽  
Sylvie Lancrenon ◽  
...  
Keyword(s):  
Bipolar Disorder ◽  
Pharmacological Treatment ◽  
Treatment Guidelines

Psychoeducation and cognitive-behavioral therapy for patients with refractory bipolar disorder: A 5-year controlled clinical trial

2014 ◽  
Vol 29 (3) ◽  
pp. 134-141 ◽  
Author(s):  
A. González Isasi ◽  
E. Echeburúa ◽  
J.M. Limiñana ◽  
A. González-Pinto
Keyword(s):  
Bipolar Disorder ◽  
Cognitive Behavioral Therapy ◽  
Pharmacological Treatment ◽  
Behavioral Therapy ◽  
Combined Treatment ◽  
Control Group ◽  
Time Points ◽  
Evaluation Time ◽  
Experimental Group

AbstractObjective:The aim of this research, which represents an additional and longer follow-up to a previous trial, was to evaluate a 5-year follow-up study of a combined treatment (pharmacological + psychoeducational and cognitive-behavioral therapy) as compared with a standard pharmacological treatment in patients with refractory bipolar disorder.Method:Forty patients were randomly assigned to either an Experimental group–under combined treatment — or a Control group — under pharmacological treatment. Data were analyzed by analysis of variance (ANOVA), with repeated measures at different evaluation time points.Results:Between-group differences were significant at all evaluation time points after treatment. Experimental group had less hospitalization events than Control group in the 12-month evaluation (P = 0.015). The Experimental group showed lower depression and anxiety in the 6-month (P = 0.006; P = 0.019), 12-month (P = 0.001; P < 0.001) and 5-year (P < 0.001, P < 0.001) evaluation time points. Significant differences emerged in mania and misadjustment already in the post-treatment evaluation (P = 0.009; P < 0.001) and were sustained throughout the study (6-month: P = 0.006, P < 0.001; 12-month: P < 0.001, P < 0.001; 5-year: P = 0.004, P < 0.001). After 5-year follow-up, 88.9% of patients in the Control group and 20% of patients in the Experimental group showed persistent affective symptoms and/or difficulties in social-occupational functioning.Conclusions:A combined therapy is long-term effective for patients with refractory bipolar disorder. Suggestions for future research are commented.

The Pharmacological Treatment of Bipolar Disorder: The Question of Modern Advances

2010 ◽  
Vol 18 (5) ◽  
pp. 266-278 ◽  
Author(s):  
Jack Hirschowitz ◽  
Alexander Kolevzon ◽  
Amir Garakani
Keyword(s):  
Bipolar Disorder ◽  
Pharmacological Treatment
Sign in / Sign up

Export Citation Format

Share Document